Report from the coordinating group ( CG) Update on Enpr-EMA - - PowerPoint PPT Presentation

report from the coordinating group cg update on enpr ema
SMART_READER_LITE
LIVE PREVIEW

Report from the coordinating group ( CG) Update on Enpr-EMA - - PowerPoint PPT Presentation

Report from the coordinating group ( CG) Update on Enpr-EMA activities, achievem ents and challenges Mark Turner EnprEMA Co-Chair An agency of the European Union Topics for discussion Overview of EnprEMA Selected achievements Enpr-EMA


slide-1
SLIDE 1

An agency of the European Union

Report from the coordinating group ( CG) Update on Enpr-EMA activities, achievem ents and challenges

Mark Turner EnprEMA Co-Chair

slide-2
SLIDE 2

Topics for discussion

Overview of EnprEMA Selected achievements Enpr-EMA represents European networks in Europe and globally

slide-3
SLIDE 3
  • An umbrella network of existing networks
  • enables collaboration and learning of individual networks from each
  • ther
  • versus the different role of the clinical trial networks which actually

conduct and perform the clinical trials.

  • The roles of Enpr-EMA include:
  • identify problems and challenges for individual networks
  • act as an European voice to raise awareness on these challenges and

difficulties on an European level

  • propose solutions – as some of the ad-hoc Enpr-EMA working groups

have done.

slide-4
SLIDE 4

Coordinating Group ( 2 0 )

Co-chaired by EMA + elected member

3 year membership

Structure - Coordinating Group

slide-5
SLIDE 5

What Enpr-EMA does not do

  • fund studies
  • act as a CRO and m anage studies
  • decide on research priorities which

remain the responsibility of – the Member States – the Commission through the Community programmes – each individual network

slide-6
SLIDE 6

Achievements

  • Expansion
  • New Subgroups proposed
  • Infections
  • Paediatric Oncology
slide-7
SLIDE 7

Achievements

  • WG “Dialogue and interaction with Ethics Committees”:
  • Paper
  • Submission of comments on proposed changes to the U.S.

Common Rule. The comments focused on two points relating to paediatric research:

  • the value of taking an international perspective when revising the

Common Rule

  • Informed Consent
slide-8
SLIDE 8

Achievements

  • WGs “How to establish communication between Enpr-EMA,

networks and industry” and “Sharing good practices within Enpr- EMA and with industry” decided to merge.

  • Paper
  • Develop a model to put on the EMA website showing how

industry can engage with Enpr-EMA/ networks and how this could benefit them

slide-9
SLIDE 9

Achievements

  • “Framework for networks to interact with industry

and regulators when implementation/ conduct

  • f

clinical trials agreed in PIPs is no longer possible”..

  • Draft SOP
slide-10
SLIDE 10
slide-11
SLIDE 11

Problems that are identified but not addressed by EnprEMA

The contrast between:

  • Volume of work

– more than 1000 PIPs have been approved leading to the recruitment of > 500,000 children over the next 5 years)

slide-12
SLIDE 12

Industry Clinical Trials for Children

slide-13
SLIDE 13

Problems that are identified but not addressed by EnprEMA

The contrast between:

  • Volume of work

– more than 1000 PIPs have been approved leading to the recruitment of > 500,000 children over the next 5 years)

  • Lack of site capacity

– Individual studies are relatively small; studies in each specialty are relatively rare. – Lack of critical mass at site and national level.

slide-14
SLIDE 14

Lessons learnt about how to build a sustainable paediatric clinical trials network

  • A number of funding streams to support networks are in place
  • Funding needs to match national health care systems
slide-15
SLIDE 15

PIP Study Sponsors Data Protocol Countries Sites

Participants

Trial Process Networks (geographical and speciality) EnprEMA

slide-16
SLIDE 16

PIP Study Sponsors Data Protocol Countries Sites

Participants

Trial Process Networks (geographical and speciality) EnprEMA

Public Sector

slide-17
SLIDE 17

Achievements Adoption of European Paediatric Clinical Trials Research Infrastructure (EPCTRI) on the 2016 Road Map of the European Strategic Forum of Research Infrastructure

  • Eligible for INFRA-DEV003 to upgrade existing infrastructures
  • Eligible for INFRA-DEV001 to scope out new infrastructures
slide-18
SLIDE 18

PIP Study Sponsors Data Protocol Countries Sites

Participants

Trial Process ECRIN (PedCRIN) ECRIN / PedCRIN Trial management: approvals etc. EPCTRI Investigation: Design EPCTRI Investigation: Site identification / training Networks (geographical and speciality) EnprEMA

Public Sector

slide-19
SLIDE 19

PIP Study Sponsors Data Protocol Countries Sites

Participants

Trial Process ECRIN (PedCRIN) ECRIN / PedCRIN Trial management: approvals etc. EPCTRI Investigation: Design EPCTRI Investigation: Site identification / training Networks (geographical and speciality) EnprEMA

Public Sector

> 400 trials a year to regulatory standards

slide-20
SLIDE 20

PIP Study Sponsors Data Protocol Countries Sites

Participants

Trial Process Networks (geographical and speciality) EnprEMA Integrated system for the design and delivery of clinical trials that meet regulatory requirements; the system is open to all Sponsors and develops sustainable capacity in high quality sites

slide-21
SLIDE 21

Global Context

North America Europe

Japan South Korea

Australia Common needs but

  • Patchwork of purposes
  • Patchwork of funding
slide-22
SLIDE 22

Global Context

North America Europe

Japan South Korea

Australia NIH PTC/ iACT PTN Enpr EMA IMI2 ECRIN EPCTRI Common needs but

  • Patchwork of purposes
  • Patchwork of funding
slide-23
SLIDE 23

Global Context

North America Europe

Japan South Korea

Australia NIH PTC/ iACT PTN Enpr EMA IMI2 ECRIN EPCTRI Common needs but

  • Patchwork of purposes
  • Patchwork of funding

M M M M C M C C C M: Management of Clinical Trials C: Coordination of a portfolio of Clinical Trials C

slide-24
SLIDE 24

Global Context

North America Europe

Japan South Korea

Australia NIH PTC/ iACT PTN Enpr EMA IMI2 ECRIN

Strat Strat

EPCTRI

Strat Off- pat Innov Innov Strat

Common needs but

  • Patchwork of purposes
  • Patchwork of funding

M M M M C M C C C M: Management of Clinical Trials C: Coordination of a portfolio of Clinical Trials I: Strategic trials: funded publically

Studies to adapt off-patent medicines to children Studies of Innovative medicines

C

Off- pat

slide-25
SLIDE 25

Global Context

North America Europe

Japan South Korea

Australia NIH PTC/ iACT PTN Enpr EMA IMI2 ECRIN

Strat Strat

EPCTRI

Strat Off- pat Innov Innov Strat

Common needs but

  • Patchwork of purposes
  • Patchwork of funding

M M M M C M C C C M: Management of Clinical Trials C: Coordination of a portfolio of Clinical Trials I: Strategic trials: funded publically

Studies to adapt off-patent medicines to children Studies of Innovative medicines

C

Off- pat

slide-26
SLIDE 26

Conclusions

EnprEMA is a thriving forum for interactions between networks, Pharma, CROs, regulators and children, young people and families EnprEMA promotes shared practice within Europe and with other parts of the world